Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

Moderna's coronavirus vaccine generated blockbuster revenue, but demand declined in the later stages of the pandemic. The company's oncology pipeline is advancing, and a potential product may be on the horizon.

The Motley Fool • Oct 21, 2026

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna's shares soared following a major Phase 3 clinical trial win. The company's vaccine platform arguably looks more promising than ever.

The Motley Fool • Oct 21, 2026

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.

Market Watch • Oct 21, 2026

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.

Zacks Investment Research • Oct 21, 2026

Moderna (MRNA) Rises Higher Than Market: Key Facts

The latest trading day saw Moderna (MRNA) settling at $245.81, representing a +1.54% change from its previous close.

Zacks Investment Research • 19 hours ago

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.

24/7 Wall Street • Oct 20, 2026

What's Going On With Moderna Stock Monday?

Moderna Inc. (NASDAQ:MRNA) shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its personalized cancer therapy this Saturday and after BofA raised its price target.

Benzinga • Oct 19, 2026

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

MarketBeat • Oct 19, 2026

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

The recent meteoric rally of MRNA shares has made Moderna a massive company. Its market cap has grown so large, in fact, that it's earned a place among Nasdaq's largest listings.

The Motley Fool • Oct 18, 2026

Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?

AI stocks have been known for explosive gains in recent years and have driven the S&P 500 higher. This year, some investors scored a much bigger win by investing in a promising biotech stock.

The Motley Fool • Oct 16, 2026